Daily pills and frequent clinic visits are a major barrier to infectious diseases prevention and treatment, especially in low- and middle-income countries (LMICs). Long-acting technologies (LATs), including injectables, implants, pills, and microneedle patches also known as microarray patches (MAPs), can…
TAG is calling for expressions of interest from civil society and community-based organizations in communities where new tuberculosis vaccines are likely to be introduced.
October Update: Ending HIV requires sustained research. TAG’s cure trials updates track clinical studies worldwide, helping advocates, researchers, and communities follow progress toward a cure.
2026 TAG Limited Art Edition To purchase this unique work, please use this form.
This article, Infections Post-inequalities: Realizing the End of Tuberculosis Through Equitable Economic Orders, explores TB as a proxy metric for the failure to dismantle colonial structures in global health and to realize the rights to health and science. Fundamentally, the…
Storytelling is a tool that can help build understanding, support discussions between members of affected communities and other stakeholders, and aid in the identification of important issues and potential solutions. These storyboards follow three individuals journeys through diagnosis, treatment and care, and the barriers they face.
The WHO Global TB Program's Accelerator Platform for Novel TB Regimens held its 12th meeting to examine the four-month HPMZ (isoniazid, rifapentine, moxifloxacin, pyrazinamide) regimen for tuberculosis treatment, covering country experiences, implementation tools, and next steps for rollout. Despite the World Health Organization's (WHO) 2022 recommendation, implementation has remained limited, with challenges such as high pill burden and medicine costs cited as potential barriers.
Treatment Action Group (TAG) is seeking a consultant to coordinate and strengthen the work of the Community Research Advisors Group (CRAG), one of the longest-running community advisory boards in tuberculosis (TB) research.
A landmark tuberculosis study showed that drug-sensitive TB can be treated in four months instead of six using the WHO-endorsed HPMZ regimen. This factsheet examines barriers to adoption, the role of new fixed-dose combinations, Global Fund GC8 funding opportunities, and advocacy strategies to expand access
The ASCENT DR-TB project, funded by Unitaid and led by the KNCV Tuberculosis Foundation, aims to improve access to shorter, safer and more effective treatment regimens for drug-resistant TB (DR-TB) and comprehensive, person-centered packages of quality care.